组长简介： 李大伟 教授/博士生导师 Prof. Dawei Li Tel: +86-21-34204744 Email: daweili@sjtu.edu.cn
成员简介
武正华：助理研究员，医学硕士。
Zhenghua Wu Assistant researcher, master of medicine
研究方向/领域
我们致力于研究在药学领域中分子生物学前沿知识的转化应用。 目前课题组研究主要集中在两个相关方向：
1、生物技术药物。主要研发哺乳动物细胞表达的血液和细胞因子生物药物和单克隆抗体药物。我们通过对分子生物学机制的研究，发现、改造、优化重组蛋白和抗体药物；并通过新型载体和细胞株筛选技术的研究，形成稳定高表达工程细胞株，以推动临床前生物技术药物研发。
2、基于细胞信号通道的药物筛选模型与药物作用机制。通过对启动子调控机制的研究，揭示肿瘤细胞信号转导的基因调控靶蛋白和靶序列，尤其是在药物作用下的细胞信号靶位改变机制，基于这些靶位，开发适用于不同肿瘤、不同药物的高效细胞筛选与机制研究系统。
Recombinant biopharmaceuticals. In this area we focus on the research and development of recombinant blood factors and therapeutic monoclonal antibodies. Our continuing research in molecular biology leads to the discovery and improvement of recombinant protein and antibody drugs. Through the improvement of expression vector and expression cell line selection technologies we are further developing these biotechnology drugs in preclinical studies.
Drug screening systems and drug mechanism study. Through the study of promoter regulatory pathway networks, we are revealing new functions of regulatory sequences, transcription factors and targeting pathways in cancer signaling and, in particular, under the influence of anticancer drugs. Information derived from these studies is being used in the development of various drug screening assay systems to support the discovery of drugs targeting various signaling pathways and cancer types.
主要成果/奖励
主要从事药学领域中分子生物学前沿知识的转化应用：研发哺乳动物细胞表达的血液和细胞因子生物药物和单克隆抗体药物；基于细胞信号通道的药物筛选模型与药物作用机制。先后承担了国家自然科学基金项目和上海市科委生物医药重点科技攻关项目，并承担上海市全英语示范课程，发表论文20余篇，其中包括三篇第一作者的PNAS五篇，授权美国专利1项，中国专利2项，申请专利5项。
My lab is committed in the area of translational and applied molecular medicine. We are currently focusing our efforts in the research and developments of improved and novel biotechnology drugs include recombinant blood factors and therapeutic monoclonal antibodies. The high expression CHO clones of recombinant human coagulation factor VIII and a promising humanized monoclonal antibody medicine 18A4HU are currently in preclinical development. In addition, we are developing novel drug screening systems and discovering new drug targets. In this area, we have developed an efficient fluorescent cell line for high throughput drug screening and identified an evolutionarily conserved drug-responsive cis-acting element that is being developed into new drug screening systems. We have over 20 Publications including 3 first author papers among total of 5 PNAS papers; One granted US patent and 2 granted Chinese patents; with 5 patent pending; Our research projects includes grants from National Natural Science Foundation of China (Dawei Li, 30771212), Shanghai Biomedical Key Scientific and Technological Projects (Dawei Li, 10431903900) and Shanghai Higher Education All English Model Lecture Project.
联系方式
Pharmacy Building 6, Minhang campus
Tel: +86-21-34204744
Email: daweili@sjtu.edu.cn
